echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The clinical development of BioVaxys is actively reviewed by the FDA

    The clinical development of BioVaxys is actively reviewed by the FDA

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 18th, BioVaxys Technology Corp.


    BioVaxys submitted CoviDTH's pre-IND meeting application and briefing package to the FDA's Center for Biologics Evaluation and Research (CBER) in March this year


    FDA may choose not to grant pre-IND review due to substantive reasons, for example, it is too early in the product development stage, or it does not provide sufficient basis for review


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.